Michael J Mauro
Overview
Explore the profile of Michael J Mauro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
2530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Atallah E, Mauro M, Sasaki K, Levy M, Koller P, Yang D, et al.
Future Oncol
. 2024 Oct;
20(38):3065-3075.
PMID: 39387441
Up to 40% of newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) discontinue treatment by 5 years, primarily due to resistance or intolerance. Rates of resistance to...
2.
Kockerols C, Valk P, Dulucq S, Nicolini F, Mahon F, Atallah E, et al.
Am J Hematol
. 2024 May;
99(8):1632-1635.
PMID: 38769689
No abstract available.
3.
Cortes J, Sasaki K, Kim D, Hughes T, Etienne G, Mauro M, et al.
Leukemia
. 2024 May;
38(7):1522-1533.
PMID: 38755421
Asciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1, which is resistant to most approved adenosine triphosphate-competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability...
4.
Sweet K, Cortes J, Apperley J, Mann M, Mauro M, Oehler V, et al.
Clin Cancer Res
. 2024 Jan;
30(1):237-238.
PMID: 38178776
No abstract available.
5.
Winn A, Atallah E, Cortes J, Deininger M, Kota V, Larson R, et al.
JAMA Netw Open
. 2023 Dec;
6(12):e2347950.
PMID: 38109114
Importance: Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response using tyrosine kinase inhibitors (TKIs) can safely attempt to stop their use. As these medications are...
6.
Hijiya N, Mauro M
Cancer Manag Res
. 2023 Aug;
15:873-891.
PMID: 37641687
Tyrosine kinase inhibitors (TKIs) have significantly changed the treatment of chronic myeloid leukemia (CML) and improved outcomes for patients with CML in chronic phase (CML-CP) and accelerated phase (AP). Now...
7.
Cortes J, Rea D, Mauro M, Tran D, Wang P, Jadhav K, et al.
J Med Econ
. 2023 Jul;
26(1):915-923.
PMID: 37431294
Objectives: To assess and compare health care resource utilization (HCRU) rates of asciminib and bosutinib at the Week 24, Week 48, and Week 96 cutoffs among 3 L + patients...
8.
Shah N, Garcia-Gutierrez V, Jimenez-Velasco A, Larson S, Saussele S, Rea D, et al.
Br J Haematol
. 2023 May;
202(5):942-952.
PMID: 37246588
Patients with chronic myeloid leukaemia in chronic phase (CML-CP) who have a sustained deep molecular response (DMR) are eligible to discontinue treatment and attempt treatment-free remission (TFR). In the DASFREE...
9.
Rea D, Boquimpani C, Mauro M, Minami Y, Allepuz A, Maheshwari V, et al.
Leukemia
. 2023 Apr;
37(5):1060-1067.
PMID: 37069326
In ASCEMBL, an open-label, randomized Phase 3 study, asciminib demonstrated superior efficacy and better safety profile compared with bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) previously...
10.
Mauro M, Hughes T, Kim D, Rea D, Cortes J, Hochhaus A, et al.
Leukemia
. 2023 Mar;
37(5):1048-1059.
PMID: 36949155
Asciminib is approved for patients with Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of...